SCARLETRED
Lead Partner
SCARLETRED is the worldwide leader in standardized skin imaging and AI powered objective skin analysis. We develop and deliver cutting edge software products and services to biopharma-, biotech- , cosmetics companies, clinical research organisations and health care experts. Our certified, ICH-GCP and EU-GDPR compliant mobile medical device software Scarletred® Vision is the first digital solution solving the problem of lacking standardization and subjective visual skin assessment in pre-clinical, clinical, and post-marketing studies. The highly scalable software platform works infrastructure as well as location independent and enables on-site and home-based monitoring of dermatologic disease as well as digital analysis of skin drug related effects. It it easy to use and reduces development time and opportunity cost in clinical RnD projects. Our digital Products and Services are delivered worldwide from our offices in Europe and USA via flexible Software as a Service (SaaS) agreements.
QuantifiCare
Innovation Partner
QuantifiCare is an Imaging CRO specialized in the management and analysis of 2D and 3D digital images in Phase I-IV multicenter and decentralized trials. With over 20 years of experience in clinical research and medical image processing, QuantifiCare has developed a strong expertise across the fields of dermatology, aesthetics, wound care and oncology. The company operates internationally from its offices in the USA, Europe, South America and Asia.
Legit.Health
Innovation Partner
Legit.Health is an AI-powered platform certified as a medical device that automates clinical endpoint collection in dermatology trials. Using clinical photographs, it objectively measures conditions like atopic dermatitis, psoriasis, and hidradenitis suppurativa (HS) with validated scores such as EASI, PASI and IHS4. Investigators receive instant objective severity calculations, reducing workload, while sponsors can monitor data in real time. Our validated algorithms ensure consistent, standardized assessments—addressing data quality challenges and supporting reliable drug development in dermatology.
Premier Research
Hosting Partner
Premier Research, LLC, is a global leader in clinical research and consulting, helping the most innovative companies turn breakthrough science into life-changing treatments. With deep therapeutic expertise, product development insight, and cutting-edge technology, we deliver personalized, end-to-end support—from preclinical planning to clinical trial execution to commercialization. Our integrated approach accelerates development and de-risks decision-making for a smarter, faster path to approval.
Dow Development Laboratories
Exhibition Partner
Dow Development Laboratories’ core expertise is in the development, manufacture, and testing of topical dermatological drug products for clinical use. Products are designed to be iseasecompatible, cosmetically elegant and physically and chemically stable. Our formulation, analytical, production, quality, and clinical labeling teams have decades of experience moving products quickly toward regulatory approval. DDL works seamlessly with its parent company Symbio Proinnovera, a global CRO with decades of success in conducting clinical trials, to rapidly advance dermatological programs through all stages of clinical development.
Therapeutics Inc.
Exhibition Partner
San Diego based, Therapeutics, Inc., The Dermatology CRO was founded in 1997. Approximately 90% of our activities are focused on developing dermatology products. TI is the only dermatology focused CRO that provides all services required to move a product concept through non-clinical and clinical stages to FDA approval. During the last 5 years: TI managed >12,000 subjects in >80 clinical studies and filed 18 INDs and IDEs in a variety of drug, device and biologic programs.
Transpharmation
 Exhibition Partner
Transpharmation is an accredited preclinical contract research organization specializing in translational pharmacology across various therapeutic areas. We offer two distinct models to support the development of dermatological therapeutics: a naturally occurring model of canine atopic dermatitis and an induced interleukin-31 (IL-31) pruritus model. These models enable the assessment of both long-term disease-modifying therapies and rapid-acting antipruritic agents. Committed to on-time data delivery and providing flexible, customized solutions, we support clients in optimizing preclinical assets for the development of life-changing medicines